Choosing the Best Second-Line Tyrosine Kinase Inhibitor in Imatinib-Resistant Chronic Myeloid Leukemia Patients Harboring Bcr-Abl Kinase Domain Mutations: How Reliable Is the IC(50)?

Development of drug resistance to imatinib mesylate in chronic myeloid leukemia (CML) patients is often accompanied by selection of point mutations in the kinase domain (KD) of the Bcr-Abl oncoprotein, where imatinib binds. Several second-generation tyrosine kinase inhibitors (TKIs) have been design...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Soverini, Simona, Rosti, Gianantonio, Iacobucci, Ilaria, Baccarani, Michele, Martinelli, Giovanni
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: AlphaMed Press 2011
Aiheet:
Leukemias
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3228229/
https://ncbi.nlm.nih.gov/pubmed/21632458
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2010-0388
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia